Pulmonary Fibrosis in COVID-19 Survivors: Predictive Factors and Risk Reduction Strategies
Pulmonary Medicine · 11.08.2020 · 2020 · 1-10
DOI: 10.1155/2020/6175964 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Pulmonary Medicine, erschienen am 11.08.2020. Verfasst von Ademola S Ojo und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Anatomical Sciences, St. George's University School of Medicine, St. George's, Grenada. Hauptthemen laut MEDLINE: Betacoronavirus, Risk Reduction Behavior. Die Arbeit wurde bisher 226-mal zitiert (Crossref) und nennt 114 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Although pulmonary fibrosis can occur in the absence of a clear-cut inciting agent, and without a clinically clear initial acute inflammatory phase, it is more commonly associated with severe lung injury. This may be due to respiratory infections, chronic granulomatous diseases, medications, and connective tissue disorders. Pulmonary fibrosis is associated with permanent pulmonary architectural distortion and irreversible lung dysfunction. Available clinical, radiographic, and autopsy data has indicated that pulmonary fibrosis is central to severe acute respiratory distress syndrome (SARS) and MERS pathology, and current evidence suggests that pulmonary fibrosis could also complicate infection by SARS-CoV-2. The aim of this review is to explore the current literature on the pathogenesis of lung injury in COVID-19 infection. We evaluate the evidence in support of the putative risk factors for the development of lung fibrosis in the disease and propose risk mitigation strategies. We conclude that, from the available literature, the predictors of pulmonary fibrosis in COVID-19 infection are advanced age, illness severity, length of ICU stay and mechanical ventilation, smoking and chronic alcoholism. With no proven effective targeted therapy against pulmonary fibrosis, risk reduction measures should be directed at limiting the severity of the disease and protecting the lungs from other incidental injuries.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Department of Anatomical Sciences, St. George's University School of Medicine, St. George's, Grenada.
- Department of Surgery, Obafemi Awolowo University Teaching Hospital Complex, Ile Ife, Nigeria.
- Department of Medicine, Obafemi Awolowo University Teaching Hospital Complex, Ile Ife, Nigeria.
- Department of Morbid Anatomy, Obafemi Awolowo University Teaching Hospital Complex, Ile Ife, Nigeria.
ORCID-Profile: Ademola S Ojo
Zitieren
APA
Ojo, A. S., Balogun, S. A., Williams, O. T., & Ojo, O. S. (2020). Pulmonary Fibrosis in COVID-19 Survivors: Predictive Factors and Risk Reduction Strategies. Pulmonary Medicine, 2020, 1-10. https://doi.org/10.1155/2020/6175964
Vancouver
Ojo AS, Balogun SA, Williams OT, Ojo OS. Pulmonary Fibrosis in COVID-19 Survivors: Predictive Factors and Risk Reduction Strategies. Pulmonary Medicine. 2020;2020:1-10. doi:10.1155/2020/6175964
BibTeX
@article{Ojo2020,
author = {Ojo, Ademola S and Balogun, Simon A and Williams, Oyeronke T and Ojo, Olusegun S},
title = {Pulmonary Fibrosis in COVID-19 Survivors: Predictive Factors and Risk Reduction Strategies},
journal = {Pulmonary Medicine},
year = {2020},
volume = {2020},
pages = {1--10},
doi = {10.1155/2020/6175964}
}
EUVIMED